\BOOKMARK [0][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{List of Tables}{}% 2
\BOOKMARK [0][-]{chapter*.4}{List of Figures}{}% 3
\BOOKMARK [0][-]{chapter*.5}{List of Abbreviations and Symbols}{}% 4
\BOOKMARK [0][-]{chapter*.8}{Acknowledgements}{}% 5
\BOOKMARK [0][-]{chapter.1}{1 Introduction}{}% 6
\BOOKMARK [1][-]{section.1.1}{1.1 Vascular Malformations}{chapter.1}% 7
\BOOKMARK [2][-]{subsection.1.1.1}{1.1.1 Common Genetic Mechanisms}{section.1.1}% 8
\BOOKMARK [1][-]{section.1.2}{1.2 Hereditary Hemorrhagic Telangiectasia}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.2.1}{1.2.1 Genetics}{section.1.2}% 10
\BOOKMARK [2][-]{subsection.1.2.2}{1.2.2 Signaling of ACVRL1, ENG, and SMAD4}{section.1.2}% 11
\BOOKMARK [2][-]{subsection.1.2.3}{1.2.3 Relationship with Sporadic Arteriovenous Malformations}{section.1.2}% 12
\BOOKMARK [1][-]{section.1.3}{1.3 Sturge-Weber Syndrome}{chapter.1}% 13
\BOOKMARK [2][-]{subsection.1.3.1}{1.3.1 Mosaic Mutation of GNAQ p.R183Q}{section.1.3}% 14
\BOOKMARK [2][-]{subsection.1.3.2}{1.3.2 Function and Activity of GNAQ}{section.1.3}% 15
\BOOKMARK [2][-]{subsection.1.3.3}{1.3.3 Mutation of GNAQ in Other Diseases}{section.1.3}% 16
\BOOKMARK [1][-]{section.1.4}{1.4 Cerebral Cavernous Malformations}{chapter.1}% 17
\BOOKMARK [2][-]{subsection.1.4.1}{1.4.1 Genetics}{section.1.4}% 18
\BOOKMARK [2][-]{subsection.1.4.2}{1.4.2 Differences Between Familial and Sporadic Disease}{section.1.4}% 19
\BOOKMARK [2][-]{subsection.1.4.3}{1.4.3 Two-Hit Mechanism}{section.1.4}% 20
\BOOKMARK [2][-]{subsection.1.4.4}{1.4.4 Signaling of the CCM Complex and its Downstream Effectors}{section.1.4}% 21
\BOOKMARK [1][-]{section.1.5}{1.5 Infantile Hemangioma \(??? Include Neg Data ???\)}{chapter.1}% 22
\BOOKMARK [0][-]{chapter.2}{2 Two-Hit Mechanism of Hereditary Hemorrhagic Telangiectasia}{}% 23
\BOOKMARK [1][-]{section.2.1}{2.1 Premise}{chapter.2}% 24
\BOOKMARK [1][-]{section.2.2}{2.2 Results}{chapter.2}% 25
\BOOKMARK [2][-]{subsection.2.2.1}{2.2.1 Telangiectasia Harmor a Somatic Mutation in ENG or ACVRL1}{section.2.2}% 26
\BOOKMARK [2][-]{subsection.2.2.2}{2.2.2 Somatic and Germline Mutations are Biallelic}{section.2.2}% 27
\BOOKMARK [2][-]{subsection.2.2.3}{2.2.3 Mutations are Consistent with Homozygous Loss of Function}{section.2.2}% 28
\BOOKMARK [2][-]{subsection.2.2.4}{2.2.4 Telangiectasia from the Same Individual Harbor Unique Somatic Mutations}{section.2.2}% 29
\BOOKMARK [1][-]{section.2.3}{2.3 Discussion}{chapter.2}% 30
\BOOKMARK [2][-]{subsection.2.3.1}{2.3.1 Evidence for a Genetic Two-Hit Mechanism}{section.2.3}% 31
\BOOKMARK [2][-]{subsection.2.3.2}{2.3.2 Sensitivity for Detecting Somatic Mutations}{section.2.3}% 32
\BOOKMARK [2][-]{subsection.2.3.3}{2.3.3 Necessary, but Not Sufficient}{section.2.3}% 33
\BOOKMARK [2][-]{subsection.2.3.4}{2.3.4 Extent of Lesional Mosaicism}{section.2.3}% 34
\BOOKMARK [2][-]{subsection.2.3.5}{2.3.5 Mutant Cell Metastasis}{section.2.3}% 35
\BOOKMARK [2][-]{subsection.2.3.6}{2.3.6 Two-Hit Mechanism for SMAD4 \046 JP-HHT}{section.2.3}% 36
\BOOKMARK [1][-]{section.2.4}{2.4 Methods}{chapter.2}% 37
\BOOKMARK [0][-]{chapter.3}{3 Mutant GNAQ Alleles Produce Distinct Disease Phenotypes}{}% 38
\BOOKMARK [1][-]{section.3.1}{3.1 Premise}{chapter.3}% 39
\BOOKMARK [1][-]{section.3.2}{3.2 Results}{chapter.3}% 40
\BOOKMARK [1][-]{section.3.3}{3.3 Discussion}{chapter.3}% 41
\BOOKMARK [1][-]{section.3.4}{3.4 Methods}{chapter.3}% 42
\BOOKMARK [0][-]{chapter.4}{4 MAP3K3 Mutations Seed Cerebral Cavernous Malformations}{}% 43
\BOOKMARK [1][-]{section.4.1}{4.1 Premise}{chapter.4}% 44
\BOOKMARK [1][-]{section.4.2}{4.2 Results}{chapter.4}% 45
\BOOKMARK [1][-]{section.4.3}{4.3 Discussion}{chapter.4}% 46
\BOOKMARK [1][-]{section.4.4}{4.4 Methods}{chapter.4}% 47
\BOOKMARK [0][-]{chapter.5}{5 PIK3CA Mutations Fuel Cerebral Cavernous Malformation Growth}{}% 48
\BOOKMARK [1][-]{section.5.1}{5.1 Premise}{chapter.5}% 49
\BOOKMARK [1][-]{section.5.2}{5.2 Results}{chapter.5}% 50
\BOOKMARK [2][-]{subsection.5.2.1}{5.2.1 PIK3CA Mutations Occur in Familial and Sporadic CCMs}{section.5.2}% 51
\BOOKMARK [2][-]{subsection.5.2.2}{5.2.2 CCMs Harbor Multiple Somatic Mutations in Different Genes}{section.5.2}% 52
\BOOKMARK [2][-]{subsection.5.2.3}{5.2.3 PIK3CA and CCM/MAP3K3 Mutations in the Same Cell}{section.5.2}% 53
\BOOKMARK [2][-]{subsection.5.2.4}{5.2.4 Developmental Venous Anomalies Predispose to Malformation}{section.5.2}% 54
\BOOKMARK [1][-]{section.5.3}{5.3 Discussion}{chapter.5}% 55
\BOOKMARK [2][-]{subsection.5.3.1}{5.3.1 Three-Hit Model of CCM Pathogenesis}{section.5.3}% 56
\BOOKMARK [2][-]{subsection.5.3.2}{5.3.2 Similarities to the Genetic Mechanism of Cancer}{section.5.3}% 57
\BOOKMARK [2][-]{subsection.5.3.3}{5.3.3 Role of Clonal Expansion in Mutagenesis}{section.5.3}% 58
\BOOKMARK [2][-]{subsection.5.3.4}{5.3.4 Therapeutic Implications}{section.5.3}% 59
\BOOKMARK [2][-]{subsection.5.3.5}{5.3.5 Distinct Properties of PIK3CA vs. CCM/MAP3K3 Mutations}{section.5.3}% 60
\BOOKMARK [1][-]{section.5.4}{5.4 Methods}{chapter.5}% 61
\BOOKMARK [0][-]{chapter.6}{6 Conclusion}{}% 62
\BOOKMARK [1][-]{section.6.1}{6.1 Model for HHT Pathogenesis}{chapter.6}% 63
\BOOKMARK [1][-]{section.6.2}{6.2 Model for CCM Pathogenesis}{chapter.6}% 64
\BOOKMARK [1][-]{section.6.3}{6.3 Contribution of Somatic Mutations to Non-Cancer Diseases}{chapter.6}% 65
\BOOKMARK [0][-]{appendix.A}{A Probability of Multiple Somatic Mutations}{}% 66
\BOOKMARK [0][-]{appendix.A}{Bibliography}{}% 67
\BOOKMARK [0][-]{appendix*.25}{Biography}{}% 68
